Stay updated on Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.

Latest updates to the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page
- Check6 days agoChange DetectedRevision from v3.3.1 to v3.3.2 appears to be a minor update to page formatting or documentation; no changes to study content, eligibility criteria, endpoints, or locations were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision indicator updated from v3.2.0 to v3.3.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedA government funding/status notice has been removed from the study page; core trial information, eligibility criteria, and contact details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedNo substantive changes detected to core study content. The information presented remains the same, including objectives, eligibility criteria, and outcomes.SummaryDifference0.3%

- Check63 days agoChange DetectedKey updates: version bump to v3.2.0 and the addition of an operating-status notice; the previous v3.1.0 reference was removed.SummaryDifference3%

- Check70 days agoChange DetectedUpdate includes a new version tag (v3.1.0) and removal of the Plasma cell myeloma resource from the Genetic and Rare Diseases Information Center section; indicates content reorganization with versioning rather than adding substantive new materials.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.